#Netherlands #Rotterdam #Sairopa B.V. #Exelixis #ADU-1805

Sairopa's Milestones in Cancer Research

Sairopa B.V., a Rotterdam-based clinical-stage biopharmaceutical company, has reached a significant milestone in its collaborative efforts with Exelixis, Inc., as of December 17, 2024. The partnership, which centers around the innovative anti-SIRPα antibody ADU-1805, has culminated in achieving clinical milestones that generated a total of $35 million in milestone payments. This progress marks a pivotal step forward in the development of therapies aimed at enhancing the immune system's ability to combat cancer.

Under the terms of the agreement between Sairopa and Exelixis, the latter holds exclusive rights to license the global development and commercialization of ADU-1805, following a detailed assessment of the clinical trial data from Sairopa's Phase 1 studies. To date, Sairopa has already received an upfront payment of $40 million and a $35 million payment contingent upon the Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for ADU-1805. Moreover, an additional $35 million has been tied to various advancements in the clinical development of ADU-1805, which is being tested both as a standalone treatment and in combination with PD-1 inhibitors.

Gurvinder S. Chahal, Sairopa's Chief Business Officer, expressed enthusiasm regarding these developments, stating, "Today's operational update signifies a step forward in the partnered effort to develop next-generation therapies for cancer patients worldwide. The advances seen within our clinical program underscore the diligent work and innovative science behind our partnership with Exelixis, bringing us closer to realizing our mission of modulating the immune system to improve outcomes for cancer patients."

Currently, ADU-1805 is undergoing evaluation in a first-in-human, open-label, multicenter Phase 1 trial, with patient enrollment already taking place across the United States and several European countries. The trial encompasses various assessments for both ADU-1805 as a monotherapy and in conjunction with pembrolizumab, aiming to gauge its safety and pharmacokinetics.

This collaboration effectively combines Exelixis' established success in oncology drug development with Sairopa's expertise in crafting innovative cancer immunotherapies. This synergy is poised to pave the way for potentially transformative treatments within the oncology space.

About Sairopa

Sairopa B.V. is dedicated to revolutionizing cancer treatment through innovative approaches that modulate the immune system. Their pipeline features ADU-1604, an anti-CTLA4 antibody, which has shown promising safety and efficacy in recent trials, and plans for a Phase 2 trial incorporating a PD-1 blocking antibody set for 2025. Additionally, they are advancing a SIRPα-PD-L1 bispecific antibody currently in preclinical development, targeting an IND filing in 2026. With a robust portfolio of therapeutic antibodies rooted in groundbreaking research and proprietary technologies, Sairopa aspires to spearhead the development of effective cancer immunotherapies. For further information, please explore Sairopa's website.

Forward-Looking Statements

This press release contains forward-looking statements, including those relating to the clinical and therapeutic prospects of ADU-1805, ADU-1604, and the SIRPα-PD-L1 bispecific antibody. The statements also pertain to Sairopa's future plans and potential for clinical and commercial success, embodying current expectations but involving inherent risks and uncertainties that could cause actual results to deviate materially from projected outcomes.